Minims Oxybuprocaine Chlorhydrate Bausch + Lomb Ireland Limited (Oxybuprocaine Hydrochloride)

Oxybuprocaine hydrochloride works by reversibly blocking voltage‑gated sodium channels on peripheral nerve membranes of the cornea and conjunctiva. This inhibition prevents sodium influx, stopping the generation and propagation of nerve impulses, which results in a temporary loss of sensation on the ocular surface.

The dosage of Minims Oxybuprocaine Chlorhydrate is determined by the prescribing clinician based on the specific procedure and patient needs. Typically, one or two drops are instilled into the conjunctival sac shortly before the intended examination or minor surgical intervention.

Safety data for oxybuprocaine hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Compared with other topical ocular anesthetics such as proparacaine or tetracaine, oxybuprocaine provides a rapid onset of anesthesia (within 30‑60 seconds) and a short duration (5‑10 minutes). Its ester‑type structure may be associated with a slightly higher incidence of allergic reactions, but it is well‑tolerated when used as directed for brief procedures.

The product should be stored at room temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct sunlight and moisture. Do not freeze the bottle, and discard any solution that appears discolored or contains particles.

Administration is topical. The patient should be instructed to look upward, pull down the lower eyelid, and instill one or two drops into the conjunctival sac. The eye should be gently closed for a few seconds to allow even distribution of the solution.

Serious risks, though rare, include corneal epithelial damage or ulceration, severe allergic reactions such as anaphylaxis, and systemic toxicity if excessive amounts are used. Prompt medical attention is required if the patient experiences persistent pain, vision changes, or signs of an allergic reaction.

Patients with a known hypersensitivity to oxybuprocaine, other ester‑type anesthetics, or any component of the formulation should avoid its use. It is also contraindicated in eyes with active severe infection or in individuals where the risk of corneal toxicity outweighs the benefit of anesthesia.